Dr. Bi-dar (Peter) Wang is a pioneer in the field of cancer genomics and prostate cancer disparities.
As a pharmacy research professor at the University of Maryland Eastern Shore (UMES), he is committed to the important research question of whether the observed disparities in prostate cancer between African Americans and European Americans are due to identifiable differences in the genomic portraits of these two populations.
Dr. Wang and his colleagues from George Washington University and Duke have recently developed aberrant mRNA splice variants as novel diagnostic biomarkers and potential therapeutic targets.
This invention was granted a US patent. His research projects have been supported by grants from the National Cancer Institute, U.S. Department of Defense, and the American Cancer Society.
His recent publications in Nature Communications and Clinical Cancer Research further demonstrated his quality/expertise in this emerging field.